# Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

> **NCT06647732** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 42 (estimated)

## Conditions studied

- Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT06647732
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2028-08-31
- **Final completion:** 2028-09-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06647732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06647732, "Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06647732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*